1. Stem Cell/Wnt Apoptosis Autophagy
  2. YAP Apoptosis Autophagy
  3. Verteporfin

Verteporfin  (Synonyms: CL 318952)

Cat. No.: HY-B0146 Purity: 99.26%
COA Handling Instructions

Vertéporfine (CL 318952) est un photosensibilisant pour la thérapie photodynamique pour éliminer les vaisseaux sanguins anormaux dans l'œil associés à des conditions telles que la dégénérescence maculaire liée à l'âge. Vertéporfine est un inhibiteur YAP qui perturbe les interactions YAP-TEAD. Vertéporfine induit l'apoptose cellulaire. Vertéporfine inhibe également l'autophagie.

Verteporfin (CL 318952) ist ein Photosensibilisator für die photodynamische Therapie zur Beseitigung der abnormen Blutgefäße im Auge, die mit Erkrankungen wie der altersbedingten Makuladegeneration verbunden sind. Verteporfin ist ein YAP-Hemmer, der die YAP-TEAD-Interaktionen stört. Verteporfin induziert die autophagy.

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation.

For research use only. We do not sell to patients.

Verteporfin Chemical Structure

Verteporfin Chemical Structure

CAS No. : 129497-78-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 152 In-stock
Solution
10 mM * 1 mL in DMSO USD 152 In-stock
Solid
5 mg USD 96 In-stock
10 mg USD 144 In-stock
50 mg USD 552 In-stock
100 mg USD 960 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 160 publication(s) in Google Scholar

Top Publications Citing Use of Products

142 Publications Citing Use of MCE Verteporfin

WB
IHC
RT-PCR
Proliferation Assay
Cell Viability Assay
IF

    Verteporfin purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Apr 1;21(1):238.  [Abstract]

    Verteporfin (13.9 µM; 10 µg/mL; 24 h) decreases the expression of YAP and CDX2 in NSCCs.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Reprod Sci. 2023 Mar 20.  [Abstract]

    Verteporfin (0.5, 1, 2 µM) decreases the expression of anti-apoptotic marker B cell leukemia 2 (Bcl2), while increases the expression of pro-apoptotic protein Bcl2-associated X protein (Bax) in Ishikawa cells, in a concentration-dependent manner.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Reprod Sci. 2023 Mar 20.  [Abstract]

    Verteporfin (0-5 µM; 24 h) decreases the viability of Ishikawa cells in a concentration-dependent manner (IC50 = 1.345 µM).

    Verteporfin purchased from MedChemExpress. Usage Cited in: Cell Res. 2022 Jun;32(6):543-554.  [Abstract]

    Survival of mice with striatal GL261 tumor injection with or without RT, saline plus laser treatment, or Verteporfin (Visudyne; 2 mg/mL; 5 μL was injected into the cisterna magna; 15 min) plus laser treatment.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Nat Neurosci. 2022 Jul;25(7):849-864.  [Abstract]

    Verteporfin (1 µM)-treated animals exposed to 640 nm in the head exhibits less mrc1a+ cells in the brain compared to non-photoactivated control animals.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Oct 5;13(1):5871.  [Abstract]

    Mice are injected with either Verteporfin (VP; 100 mg/kg) or vehicle (corn oil) from the postnatal 7 days at 3-day intervals for 14 days. The immunohistochemical assay shows that the expression of TFRC and COX2 is higher in Bnc1tr/tr control mouse ovaries than in Bnc1+/+ control mouse ovaries. Intriguingly, VP treatment partially rescues TFRC and COX2 expression in Bnc1tr/tr mouse ovaries.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    The expression levels of Hippo-YAP signaling downstream regenerative genes (Ctgf, Ankrd1 and Cyr61) are effectively inhibited by Verteporfin (VP; 100 µM) compared to their expression in the blank control group.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    The protective effects of TNIP3 against cell inflammation and cell death were largely abolished by Verteporfin (VP; 100 µM) administration.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 µM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 µM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Mar;30(3):229-243.  [Abstract]

    The representative images of dCLNs and sCLNs 2 weeks after striatal injection of GL261 or B16 cells into mice treated with Vehicle + Laser or =Verteporfin (Visudyne; 2 mg/mL; 5 μL was injected into the cisterna magna; 15 min) + Laser.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]

    Verteporfin displays a complete suppression of viral CPE at 0.31 µM. Viral N protein expression in infected Vero E6 cells was assessed by immunofluorescence.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]

    Protoporphyrin IX and Verteporfin effectively prevent SARS-CoV-2 infection in the mouse model expressing human ACE2. Much fewer cells expressed viral N protein in the Protoporphyrin IX and Verteporfin (20 µM) groups compared to the DMSO group.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2019 Sep 16;36(3):302-318.e7.  [Abstract]

    Combined treatment of GFAP-Ptch tumor cells with Verteporfin (VP; 24 hours) and CD532 additively decreases proliferation of ZIC1+ tumor cells relative to individual treatments.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2019 Jan 3;73(1):7-21.e7.  [Abstract]

    Control low metastatic MDA-MB-231 cells or cells overexpressing OTUB2-WT, pretreated with or without Verteporfin (VP, 10 µM) are intracardially injected into nude mice.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2019 Mar;107:29-40.  [Abstract]

    Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2019 Mar;107:29-40.  [Abstract]

    Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.

    Verteporfin purchased from MedChemExpress. Usage Cited in: Front Cell Neurosci. 2018 Dec 11;12:489.  [Abstract]

    OECs are treated with vehicle (0.1% DMSO), Y27632 (10 μM) or verteporfin (5 μM) for 24 h and performed WB analysis.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation[3].

    IC50 & Target

    IC50: YAP-TEAD interaction

    In Vitro

    Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 μM, 2.11 μM, and 5.61 μM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    718.79

    Formula

    C41H42N4O8

    CAS No.
    Appearance

    Solid

    Color

    Brown to black

    SMILES

    C[C@]1(/C2=C/C(N3)=C4C)C(C(/C=C(C(C)=C/5C=C)\NC5=C/C6=N/C(C(CCC(OC)=O)=C6C)=C\C3=C4CCC(O)=O)=N2)=CC=C(C(OC)=O)[C@H]1C(OC)=O.C[C@]7(/C8=C/C(N9)=C%10C)C(C(/C=C(C(C)=C/%11C=C)\NC%11=C/C%12=N/C(C(CCC(O)=O)=C%12C)=C\C9=C%10CCC(OC)=O)=N8)=CC=C(C(OC)=O)[C@H]7C(OC)=O

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (69.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.3912 mL 6.9561 mL 13.9123 mL
    5 mM 0.2782 mL 1.3912 mL 2.7825 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (6.96 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (6.96 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.58%

    References
    Cell Assay
    [1]

    PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and 240 nM) and BMS-354825 (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combination are measured after 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfin and BMS-354825, a normalized isobologram and fraction affectedcombination index (CI) plot are made using CompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additive effects, and below 1.0 synergistic effects.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Mice: PhLO cells (1.0×107/mouse) are injected intravenously into 6-week-old male NOG mice, which are then treated with vehicle, verteporfin (140 mg/kg/day), BMS-354825 (20 mg/kg/day), and a combination of these drugs from days 22 to 28. Verteporfin is administered by continuous subcutaneous infusion (c.s.c.) using Alzet osmotic pumps. An intraperitoneal injection (i.p.) is performed for BMS-354825. All mice are sacrificed on day 28 and the chimerism of leukemia cells is investigated by flow cytometer using an anti-human CD19 antibody and antimouse CD45 antibody. Blood concentrations of verteporfin are calculated by LCMS-2020.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMF / DMSO 1 mM 1.3912 mL 6.9561 mL 13.9123 mL 34.7807 mL
    5 mM 0.2782 mL 1.3912 mL 2.7825 mL 6.9561 mL
    10 mM 0.1391 mL 0.6956 mL 1.3912 mL 3.4781 mL
    DMSO 15 mM 0.0927 mL 0.4637 mL 0.9275 mL 2.3187 mL
    20 mM 0.0696 mL 0.3478 mL 0.6956 mL 1.7390 mL
    25 mM 0.0556 mL 0.2782 mL 0.5565 mL 1.3912 mL
    30 mM 0.0464 mL 0.2319 mL 0.4637 mL 1.1594 mL
    40 mM 0.0348 mL 0.1739 mL 0.3478 mL 0.8695 mL
    50 mM 0.0278 mL 0.1391 mL 0.2782 mL 0.6956 mL
    60 mM 0.0232 mL 0.1159 mL 0.2319 mL 0.5797 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Verteporfin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Verteporfin
    Cat. No.:
    HY-B0146
    Quantity:
    MCE Japan Authorized Agent: